Quad Medicine (CEO Seungki Baek), a medical microneedle platform specialist, announced on the 29th a contract amendment to add GLP non-clinical trials for the clinical entry of the typhoid vaccine microneedle patch (MAP) being jointly developed with the global pharmaceutical company GlaxoSmithKline (GSK).
This contract amendment will include repeat-dose toxicity and skin irritation/sensitization testing in the existing milestone agreement signed in 2024. Quad Medicine will also receive an additional $700,000 in research and development expenses over a 12-month period. Through these nonclinical trials, the two companies plan to secure the safety data necessary for entering overseas clinical trials and accelerate development.
In 2022, Quad Medicine signed a joint research and material transfer agreement with GSK to integrate its microneedle technology into a Shigella vaccine. The collaboration has since expanded to include a licensed typhoid vaccine. Through a phased milestone structure, Quad Medicine has demonstrated technological progress at each development stage, earning the trust of global pharmaceutical companies.
Baek Seung-ki, CEO of Quadmedicine, said, “We are building a foundation for long-term value creation by receiving substantial technology fees based on step-by-step technology verification,” and “We will continue to expand the scope of application of the microneedle platform based on future collaboration with GSK.”
- See more related articles
You must be logged in to post a comment.